Skip to content
Medical Health Aged Care, Research Development

Genetic Risk for High Blood Pressure Associated with Poorer Cognitive Function

Centre for Healthy Brain Ageing (CHeBA), UNSW Sydney 2 mins read

New research led by UNSW Sydney’s Centre for Healthy Brain Ageing (CHeBA) finds that genetic risk for higher blood pressure even in those in their 40s and 50s may contribute to poorer cognitive function.

“This research is groundbreaking,” says Dr Matt Lennon, lead author on the study and a researcher at the Centre for Healthy Brain Ageing (CHeBA).

“Previously, the literature generally indicated that the cognitive effects of high blood pressure were not seen until late in life. We have found that there are subtle but real changes several decades earlier.

“However, the relationship of blood pressure with brain function is complex. Those with a genetic predisposition to higher blood pressure had significantly better reaction time, particularly in males,” says Dr Lennon.

“We know that high blood pressure is remarkably common in the community, especially among males, and part of this may be explained by the fact that there are some genetic advantages to this in reaction time - measuring how quickly an individual responds to a stimulus - although ones that come at the long-term costs of poorer cognitive health and greater risks of heart attacks and strokes,” says Dr Lennon.

The study, published in the journal Hypertension, used novel approaches to generate deeper insights into a previously studied area. It used “big data” from the UK Biobank, including 448,575 participants, and differed from many previous studies by using a genetic quantification of blood pressure risk rather than measurement of blood pressure directly, which is frequently inaccurate.

The study suggests that in the future prevention strategies for cognitive decline may be more targeted and personalised based on an individual’s genetic risk for high or low blood pressure, as well as their age and sex. Interestingly, the study also found that for those in their 60s marginally higher blood pressures may be optimal for maintaining cognitive ability, compared to those in their 40s and 50s.

Co-Director of CHeBA and co-author Professor Perminder Sachdev, said “Hypertension impacts over 1 billion individuals worldwide and is the single, most prevalent risk factor for cognitive decline.

“It is critical we understand the complexities of this modifiable risk factor for dementia, particularly in people in their 40s and 50s, to develop strategies of earlier intervention and prevention of cognitive decline and dementia,” said Professor Sachdev.


Key Facts:


About us:

www.cheba.unsw.edu.au


Contact details:

Heidi Douglass

0435579202

[email protected]

Media

More from this category

  • CharitiesAidWelfare, Medical Health Aged Care
  • 17/12/2025
  • 06:00
Leukaemia Foundation

Leukaemia Foundation welcomes South Australian Government commitment to establish dedicated CAR T therapy service

The Leukaemia Foundation has welcomed the announcement by theMalinauskas Labor Government that South Australia is establishing a dedicated CAR T-cell therapy service as a line of treatment for people living with blood cancer – marking a major advancement in cancer care in the State. The new service, expected to commence by mid-2026, will significantly improve access to this highly specialised, life-saving treatment and reduce the need for South Australians to travel interstate for care. Leukaemia Foundation Chief Executive Officer Chris Tanti said the announcement represented a huge win for blood cancer patients and their families. “This is a landmark step…

  • Medical Health Aged Care
  • 17/12/2025
  • 01:10
WW International Inc.

Weight Watchers Launches a Fully Integrated Platform for the GLP-1 Era

A redesigned Weight Watchers experience pairs comprehensive GLP-1 support with personalised nutrition, coaching, community support, and cutting-edge technology to help members meet their weight loss goals and achieve results that lastNEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight management, today introduced a new, fully integrated experience bringing together comprehensive support for members on GLP-1 medications, personalised nutrition, behavioural support, coaching, and community within a redesigned app and digital platform. Built for a new era of weight management and long-term health, the new integrated offering delivers coordinated, evidence-based…

  • Medical Health Aged Care
  • 16/12/2025
  • 12:11
Esco Aster Pte. Ltd.

Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform

SINGAPORE–BUSINESS WIRE– Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.